A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants

NCT05541315 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-88260237
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC